AMRX
Amneal·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Consensus Rating "Buy"
Ample Liquidity
High Cash/net Profit Ratio
Low Cash Short-term Debt Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AMRX
Amneal Pharmaceuticals, Inc.
A manufacturer engaged in the development and production of high-value generic pharmaceutical products
400 Crossing Boulevard, Bridgewater, NJ 08807
--
Amneal Pharmaceuticals, Inc., is a Delaware corporation. The Company is a global pharmaceutical company that develops, manufactures, markets and distributes a diverse portfolio of essential medicines, including retail generics, injectables, biosimilars and specialty branded medicines. The Company operates primarily in the United States (" US "), India and Ireland, selling directly or indirectly to wholesalers, distributors, hospitals, government agencies, chain pharmacies and individual pharmacies.
Earnings Call
Q1/2025
Estimate EPS0.15
Actual EPS0.21
Estimate Revenue715.49M
Actual Revenue695.42M
Amneal's Q1 2025 Earnings Call: Unraveling Contradictions in Biosimilars, CREXONT Strategies, and Generic Pricing
May 02,2025 07:28
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.17
Actual EPS0.25
Estimate Revenue744.56M
Actual Revenue725.00M
Amneal Pharmaceuticals' 2025Q2 Earnings Call: Key Contradictions on RYTARY, CREXONT, and Margin Strategies
Aug 05,2025 03:06
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
AMRX has released its 2025 Q3 earnings. EPS was reported at 0.17, versus the expected 0.14, beating expectations. The chart below visualizes how AMRX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AMRX has released its 2025 Q3 earnings report, with revenue of 784.51M, reflecting a YoY change of 11.68%, and net profit of 18.13M, showing a YoY change of 54.22%. The Sankey diagram below clearly presents AMRX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
